A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI).
Pinato DJ, North BV, Sharma R. · 2012
Read A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). by Pinato DJ, North BV, Sharma R. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3326674.txt.
Introduction
Pinato, North, and Sharma built a simple survival score for liver cancer from two routine blood values, reporting in 2012. Growing evidence shows that whole body inflammation predicts poor outcomes across cancers, whatever the stage. Their score combines albumin, a nutrition linked protein, with the count of lymphocytes, a type of immune cell, both measured when patients first arrive.
Patients whose combined value fell below the cutoff had a poor score and died sooner, in a group of more than one hundred patients treated in London over two decades. The score predicted survival even after accounting for tumor spread, clots in the liver's vein, and standard staging. It held up again in a separate matched group of patients from another setting. The authors offer the score as a cheap, validated way to flag high risk liver cancer patients.
Catalog record
| CREATOR | Pinato DJ, North BV, Sharma R. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI) By D J Pinato, B V North, R Sharma Published in: British Journal of Cancer DOI: 10.1038/bjc.2012.92 ABSTRACT Background: There is increasing evidence that the presence of an ongoing systemic inflammatory response is a stage-independent predictor of poor outcome in patients with cancer. The aim of this study was to investigate whether an inflammation-based prognostic score, the prognostic nutritional index (PNI), is associated with overall survival (OS) in patients with hepatocellular carcinoma (HCC). Methods: All patients with a new diagnosis of HCC presenting to the Medical Oncology Department, Hammersmith Hospital between 1993 and 2011 (n=112) were included. Demographic and clinical data were collected. Patients in whom the combined albumin (g l−1) × total lymphocyte count × 109 l−1 was ⩾45, at presentation, were allocated a PNI score of 0. Patients in whom this total score was <45 were allocated a score of 1. Univariate and multivariate analyses were performed to identify clinicopathological variables associated with OS. Independent predictors of survival identified on multivariate analysis were validated in an independent, stage-matched cohort of 68 patients. Results: Univariate analyses showed that PNI (P=0.003), intrahepatic spread (P<0.001), the presence of extrahepatic disease (P=0.006), portal vein thrombosis (P=0.02), tumour multifocality (P=0.003), alfa-fetoprotein >400 ng ml−1 (P<0.001) and Barcelona Clinic Liver Cancer score (P<0.01) were all predictors of OS in the training set. Multivariate analysis revealed the PNI (P=0.05), presence of extrahepatic disease (P<0.001) and degree of intrahepatic spread (P<0.001) as independent predictors of worse OS in this population. The PNI retained independent prognostic value in the validation set (P<0.001). Conclusion: The presence of a systemic inflammatory response, as measured by the PNI, is an independent and externally validated predictor of poor OS in patients with HCC. Hepatocellular carcinoma (HCC) is the sixth most common neoplasm, and the third most lethal accounting for more than 600 000 deaths per year worldwide (Parkin et al, 2005). In countries with active surveillance programs, HCC is diagnosed at an early stage in 30 to 40% of patients and is amenable to potentially curative treatments, such as surgical resection and liver transplantation. However, for the majority of patients palliation is the only treatment option, owing to the fact that most tumors are diagnosed at an advanced stage. Sorafenib is the standard of care in patients with advanced disease, but has limited efficacy, with only a 3-month improvement in overall survival (OS) (Llovet et al, 2008). There is a need therefore to further delineate prognostic determinants of survival in order to better stratify those patients likely to benefit from treatment in order to avoid unnecessary toxicity and morbidity. The pathogenesis of HCC is based on inflammation such that the chronically inflamed liver parenchyma represents a preneoplastic environment in which HCC can arise as a result of the exposure to a plethora of pro-inflammatory stimuli such as infection by hepatotropic viruses, iron or copper accumulation or ethanol consumption (Berasain et al, 2009). Unlike other malignancies, survival in HCC patients is peculiarly influenced by the underlying liver function along with the extent of spread of the primary tumour (Bruix et al, 2001). The most commonly used prognostic algorithms variably incorporate predictors reflecting liver functional reserve, performance status as well as the tumour stage, however despite there being seven different prognostic scores, there is little consensus in the literature as to the most reliable (Camma and Cabibbo, 2009). The two most commonly used scores are the Barcelona Clinic Liver Cancer (BCLC) (Llovet et al, 1999) and Cancer of the Liver Italian Program (CLIP) scores (Investigators CLIP, 1998). The BCLC score is an optimally designed treatment algorithm but recent evidence has shown its limited predictive value in estimating survival in patients with advanced HCC (Huitzil-Melendez et al, 2010). Despite having shown good predictive capacity across all the stages of HCC (Hsu et al, 2010), the CLIP score subcategorizes patients in seven prognostic strata, therefore reducing its applicability to routine clinical practice. There is a need therefore for a reliable, easy to use prognostic score. There is increasing evidence showing that the presence of a systemic inflammatory response, as indicated by an elevated circulating C-reactive protein (CRP) concentration, is associated with poor survival in patients with malignancy, including HCC (Hashimoto et al, 2005; Nagaoka et al, 2007). Furthermore, the presence of an inflammatory response is proposed to be pathogenic in the development of cancer-associated malnutrition (Argiles et al, 2003a, 2003b). Nutritional impairment in turn is correlated with poor performance status, shorter survival, and increased mortality in patients with cancer (Andreyev et al, 1998; Dewys et al, 1980; Rey-Ferro et al, 1997; Jagoe et al, 2001). This is of particular concern in patients with HCC, given the concomitant underlying illnesses and possible impaired nutritional status secondary to cirrhosis (Meng et al, 2010). The prognostic nutritional index (PNI) has been shown to be a prognostic marker in a number of gastrointestinal malignancies (Nozoe et al, 2002, 2010; Kanda et al, 2011), and, more recently, in a large study by Proctor et al (2011), the PNI was found to predict prognosis in malignancy regardless of the site of origin. The aim of the present study is to examine the relationship between the PNI and survival in patients with HCC. PATIENTS AND METHODS We conducted a retrospective analysis of all the patients with a diagnosis of HCC presenting to the Medical Oncology Department, Hammersmith Hospital between 1993 and 2011, excluding those cases with a positive history of inflammatory disease or active concomitant infection. All the patients included satisfied the diagnosis of HCC made according to radiological or histological criteria as recommended by the American Association for the Study of the Liver guidelines (Bruix and Sherman, 2005). Clinical variables, including demographic data, complete blood picture, albumin, alpha-fetoprotein (AFP), staging of the tumour, including the number of focal hepatic lesions, maximum diameter detected during contrast enhancement phase and degree of intra-hepatic spread, and Child–Turcotte–Pugh (CTP) class were collected. The presence of liver cirrhosis was diagnosed using clinical and radiological criteria (computerised tomography scan) in all patients. A proportion of the cirrhotic subjects included in this study had histological evidence of liver cirrhosis (45%). Overall (cancer-specific) survival was computed from the time of referral to our unit. The PNI was calculated as described previously (Nozoe et al, 2010) where combined albumin (g l−1) × total lymphocyte count × 109 l−1 ⩾45, at presentation, were allocated a PNI score of 0. Patients in whom this total was <45 were allocated a PNI score of 1, where a PNI of 1 is indicative of severe nutritional impairment and PNI of 0 is normal. The significance of the tested prognostic models was externally validated using an independent set of consecutive, stage-matched patients presenting to the St Mary's and Charing Cross Hospitals (n=68). By using OS as a measure of outcome we further evaluated the independent prognostic power of the PNI in comparison with commonly used prognostic scores, including the CLIP score and the BCLC staging system on the complete set of patients (n=180). Both CLIP and BCLC prognostic models were calculated as previously described (Investigators CLIP, 1998; Llovet et al, 1999). Each score was further tested for homogeneity, discrimination and